CoChat
Cited by 89

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety

Open access
Gavish, D., Leibovitz, E., Shapira, I., Rubinstein, A. · 2000 · Journal of Internal Medicine

Abstract

Gavish D, Leibovitz E, Shapira I, Rubinstein A (Wolfson Medical Center, Holon, and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel). Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000; 247: 563–569. Objective. To determine the efficacy and safety of a statin–fibrate combination in diabetes patients. Design. An open 21‐month trial in which each patient first received the single drug for 6 months and then a combination of the two for 1 year. Setting. Three lipid clinics in university‐based tertiary care hospitals. Patients. One hundred and forty‐eight patients with type 2 (non‐insulin‐dependent, NIDDM) diabetes mellitus under stable control for 3 months by means of diet and oral hypoglycaemic medication. Intervention. Patients from one clinic (n = 48) received bezafibrate slow release (400 mg day–1), and patients from the other two clinics (n = 100) received simvastatin 20 mg day–1. Six months later, all patients were switched to a daily combination of 400 mg bezafibrate slow release and 20 mg simvastatin for 1 year. Results. The combination of statin and fibrate led to a 23% reduction in total cholesterol, 42% reduction in triglycerides, 29% reduction in LDL‐c, 25% increase in HDL‐c, 10% decrease in fibrinogen and 19% reduction of Lp(a) levels, and a decrease in the cholesterol/HDL‐c ratio (from 8.9 to 5.4) in all 148 patients. Cardiovascular (CV) event rate was significantly reduced from 9.5% during the first 6 months of the study to less than 2% during the last year of the study (whilst on combination Rx). Side‐effects with all treatments included only two patients who developed myopathy when on the combined regimen and one on the single statin regimen. However, plasma creatinine phosphokinase (CPK) levels doubled (but remained within the normal range) in most of the patients on combination therapy, compared with only a mild increase in patients receiving a single medication. Conclusions. The statin and fibrate combination was found to be more efficacious than a single medication for treatment of diabetic dyslipidaemia, as evidenced by improvement in the lipoprotein profile, reductions in Lp(a), fibrinogen and CV event rate, and almost no clinically significant side‐effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2796.2000.00646.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 89

Metadata

Authors
Gavish, D., Leibovitz, E., Shapira, I., & Rubinstein, A.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2000-05
Volume
247
Issue
5
Pages
563-569
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2095451652
Cited by
89
References
3
FWCI
11.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. https://app.cochat.ai/papers/10.1046/j.1365-2796.2000.00646.x
The paper
Gavish, D., Leibovitz, E., Shapira, I., & Rubinstein, A. (2000). Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.2000.00646.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.